{"filings":[{"id":500157,"accession_number":"0001213900-26-058495","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-05-18T20:33:00+00:00","items":["5.02"],"status":"ready","headline":"60 Degrees Pharmaceuticals appoints Eric Francois to Board of Directors","event_type":"leadership","confidence":"high","bullets":["Eric Francois appointed to board effective May 13, 2026; compensation consistent with standard non-employee director arrangements.","Francois brings over 20 years of healthcare and life sciences leadership; currently independent director at CERo Therapeutics (CERO).","Previously CFO of SCYNEXIS (SCYX), raised over $300M through FDA approval and launch; earlier MD in healthcare investment banking at Raymond James and Credit Suisse.","No family relationships or material transactions with company; appointment not pursuant to any arrangement with others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111160,"accession_number":"0001213900-26-032352","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals corrects beneficial ownership disclosure in March 13 prospectus","event_type":"other_material","confidence":"high","bullets":["March 13 prospectus supplement incorrectly reported affiliate's beneficial ownership as 21,490 shares; correct is 23,367.","Error originated from a September 2025 Form 4 and propagated through subsequent filings.","Post-1-for-4 reverse split, corrected affiliate ownership is 16,781 shares vs previously reported 15,905.","No other information in the March 13 prospectus supplement is affected by this correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111159,"accession_number":"0001213900-26-027756","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals files updated legal opinion for ATM program","event_type":"other_material","confidence":"high","bullets":["Filed updated legal opinion of Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.","Opinion confirms validity of shares sold under Sales Agreement dated September 5, 2025 with HC Wainwright & Co.","No changes to the terms of the ATM Program; opinion is procedural for ongoing offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111158,"accession_number":"0001213900-26-027008","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals files updated legal opinion for ATM program","event_type":"other","confidence":"high","bullets":["Filed updated legal opinion from Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.","Opinion confirms validity of shares sold under Sales Agreement with HC Wainwright & Co. dated Sept 5, 2025.","No changes to terms of ATM Program; filing is procedural legal update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111157,"accession_number":"0001213900-26-015239","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals regains Nasdaq compliance on minimum bid price; delisting hearing cancelled","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 11 confirming compliance with minimum bid price rule 5550(a)(2).","Prior delisting notice from Jan 20, 2026 was appealed and stayed pending hearing.","Hearing scheduled for Feb 19, 2026 has been cancelled; matter closed.","Company's common stock and warrants continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111156,"accession_number":"0001213900-26-007330","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["3.01","7.01"],"status":"ready","headline":"Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.","Company ineligible for compliance period due to 1-for-5 reverse stock split on Feb 24, 2025.","Warrants also subject to delisting under Nasdaq Listing Rule 5560(a).","Company paid $20,000 hearing fee and appealed, staying suspension pending panel decision.","No assurance the Nasdaq Panel will grant continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111155,"accession_number":"0001213900-26-006179","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals to effect 1:4 reverse stock split effective Jan 20, 2026","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:4 ratio effective Jan 20, 2026 at 12:01 AM ET before market open.","Intended to regain compliance with Nasdaq minimum bid price requirement; symbol remains SXTP.","Shares outstanding reduce from ~5.15M to ~1.29M; fractional shares rounded up to whole share.","Approved by stockholders on Oct 8, 2025 and board on Dec 17, 2025; Delaware certificate filed.","All outstanding options, warrants, and equity plans adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111154,"accession_number":"0001213900-26-002359","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals provides investor presentation via RedChip webinar; no specific details disclosed","event_type":"other_material","confidence":"low","bullets":["Company made investor presentation available on January 8, 2026, in connection with RedChip webinar.","Presentation covers updated clinical development timelines and regulatory strategy (no details disclosed).","Filing includes standard forward-looking statement disclaimer; no financial guidance provided.","Presentation exhibit (Ex. 99.1) contains only cover page and disclaimer, not slide content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127790,"accession_number":"0001213900-25-098131","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"60 Degrees Pharma shareholders approve reverse split, equity plan amendment at annual meeting","event_type":"other","confidence":"high","bullets":["Five directors elected: Geoffrey Dow, Charles Allen, Cheryl Xu, Stephen Toovey, Paul Field.","Amendment to 2022 Equity Incentive Plan approved, increasing available shares by 250,000.","Reverse stock split authorized at ratio ranging from 1:3 to 1:10, as determined by the Board.","Ratification of RBSM LLP as independent registered public accounting firm for FY2025.","Adjournment proposal approved; quorum of ~40% of outstanding shares was present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144552,"accession_number":"0001213900-25-085853","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals presents at H.C. Wainwright; no specific updates disclosed in filing","event_type":"other_material","confidence":"low","bullets":["CEO Geoff Dow scheduled to present to investors starting September 9, 2025.","Slide deck furnished to investors; filing text does not contain its substantive content.","No financial figures, guidance, or pipeline milestones provided in the 8-K.","Company is an emerging growth company listed on Nasdaq under SXTP and SXTPW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144551,"accession_number":"0001213900-25-085040","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals enters $1.4M ATM offering with H.C. Wainwright, terminates prior ATM","event_type":"other_material","confidence":"high","bullets":["Entered ATM Sales Agreement with H.C. Wainwright to sell up to $1,397,533 of common stock.","Wainwright receives 3.0% commission on gross proceeds; sales method is 'at the market'.","Terminated prior ATM agreement with Wallachbeth Capital LLC effective September 3, 2025, via waiver of notice period.","Issuance will be under existing Form S-3 shelf (File No. 333-280796) with a prospectus supplement.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144550,"accession_number":"0001213900-25-065718","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"60 Deg Pharma closes $5M public offering, up to $10M with warrant exercise","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5M from sale of 2,631,578 units (share/pre-funded warrant + warrants) at $1.90/unit.","Short-term Series A-2 warrants (18-mo term) could add $5M if fully cash-exercised; no guarantee.","Net proceeds earmarked for working capital and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent; offering closed July 16, 2025.","Offering made under effective S-1 filed July 7, 2025 (SEC File No. 333-288550)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}